SCHEMBL1864549

SCHEMBL1864549

CN(C)CC(CC1CCCCC1)NC(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 6/20 0.53
CTSS P25774 2/20 0.53
CYP3A4 P08684 1/20 0.44
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
CTSL P07711 2/20 0.42
CTSB P07858 2/20 0.42
CTSH P09668 2/20 0.42
CACNA1B Q00975 1/20 0.41
AAK1 Q2M2I8 2/20 0.40
EPHX1 P07099 1/20 0.40
KMT2A Q03164 1/20 0.38
GAA P10253 1/20 0.38
REN P00797 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1864551 1.00 CTSK (0.53) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL12632066 0.88 CTSK (0.46) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL3599923 0.87 CTSK (0.51) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL3599920 0.87 CTSK (0.51) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL272474 0.87 CTSK (0.51) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL12631585 0.85 CTSK (0.41) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL55961 0.85 CTSK (0.56) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL1424703 0.85 CTSK (0.56) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL8269725 0.85 CTSK (0.56) CTSKCTSSCYP3A4HDAC4HDAC1
SCHEMBL57254 0.85 CTSK (0.56) CTSKCTSSCYP3A4HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455521-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-06-04 US disclosed
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. 2011-05-05 US disclosed
US-7754737-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-07-13 US disclosed
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors VITAE PHARMACEUTICAL, INC (US) 2009-01-15 US disclosed
EP-1807078-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2007-07-18 EP disclosed
WO-2006042150-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors DNPEP, PEPD, ACE CTSK 31/4885CTSS 138/4885CYP3A4 2361/4885
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors DNPEP, PEPD, ACE CTSK 31/4885CTSS 138/4885CYP3A4 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.